These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23325657)

  • 21. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.
    Liu Z; Diaz LA; Troy JL; Taylor AF; Emery DJ; Fairley JA; Giudice GJ
    J Clin Invest; 1993 Nov; 92(5):2480-8. PubMed ID: 7693763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humanization of autoantigen.
    Nishie W; Sawamura D; Goto M; Ito K; Shibaki A; McMillan JR; Sakai K; Nakamura H; Olasz E; Yancey KB; Akiyama M; Shimizu H
    Nat Med; 2007 Mar; 13(3):378-83. PubMed ID: 17322897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models.
    Ujiie H; Yoshimoto N; Natsuga K; Muramatsu K; Iwata H; Nishie W; Shimizu H
    Front Immunol; 2019; 10():1410. PubMed ID: 31275329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoreactivity to bullous pemphigoid 180: is this the link between subepidermal blistering diseases and oral lichen planus?
    Shipman AR; Cooper S; Wojnarowska F
    Clin Exp Dermatol; 2011 Apr; 36(3):267-9. PubMed ID: 20569254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.
    Leighty L; Li N; Diaz LA; Liu Z
    Arch Dermatol Res; 2007 Nov; 299(9):417-22. PubMed ID: 17879094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
    Ujiie H
    J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.
    Karsten CM; Beckmann T; Holtsche MM; Tillmann J; Tofern S; Schulze FS; Heppe EN; Ludwig RJ; Zillikens D; König IR; Köhl J; Schmidt E
    Front Immunol; 2018; 9():488. PubMed ID: 29599777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
    Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
    J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cloning of a cDNA encoding the porcine type XVII collagen noncollagenous 16 A domain and localization of the domain to the upper part of porcine skin basement membrane zone.
    Xu L; Olivry T; Chan LS
    Vet Dermatol; 2004 Jun; 15(3):146-51. PubMed ID: 15214950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid.
    Schulze FS; Beckmann T; Nimmerjahn F; Ishiko A; Collin M; Köhl J; Goletz S; Zillikens D; Ludwig R; Schmidt E
    Am J Pathol; 2014 Aug; 184(8):2185-96. PubMed ID: 25043618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.
    Liu Z; Sui W; Zhao M; Li Z; Li N; Thresher R; Giudice GJ; Fairley JA; Sitaru C; Zillikens D; Ning G; Marinkovich MP; Diaz LA
    J Autoimmun; 2008 Dec; 31(4):331-8. PubMed ID: 18922680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of complement in experimental bullous pemphigoid.
    Liu Z; Giudice GJ; Swartz SJ; Fairley JA; Till GO; Troy JL; Diaz LA
    J Clin Invest; 1995 Apr; 95(4):1539-44. PubMed ID: 7706459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice.
    Hirose M; Recke A; Beckmann T; Shimizu A; Ishiko A; Bieber K; Westermann J; Zillikens D; Schmidt E; Ludwig RJ
    J Immunol; 2011 Aug; 187(3):1176-83. PubMed ID: 21705619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IgE autoantibodies against the intracellular domain of BP180.
    Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
    Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded by bullous pemphigoid antigen cDNA.
    Rico MJ; Korman NJ; Stanley JR; Tanaka T; Hall RP
    J Immunol; 1990 Dec; 145(11):3728-33. PubMed ID: 1700993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
    Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.
    Pigors M; Patzelt S; Reichhelm N; Dworschak J; Khil'chenko S; Emtenani S; Bieber K; Hofrichter M; Kamaguchi M; Goletz S; Köhl G; Köhl J; Komorowski L; Probst C; Vanderheyden K; Balbino B; Ludwig RJ; Verheesen P; Schmidt E
    J Pathol; 2024 Feb; 262(2):161-174. PubMed ID: 37929639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida.
    Iwata H; Kitajima Y
    Exp Dermatol; 2013 Jun; 22(6):381-5. PubMed ID: 23651418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models.
    Sasaoka T; Ujiie H; Nishie W; Iwata H; Ishikawa M; Higashino H; Natsuga K; Shinkuma S; Shimizu H
    J Invest Dermatol; 2018 Jun; 138(6):1260-1267. PubMed ID: 29391250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-Terminal Processing of Collagen XVII Induces Neoepitopes for Linear IgA Dermatosis Autoantibodies.
    Toyonaga E; Nishie W; Izumi K; Natsuga K; Ujiie H; Iwata H; Yamagami J; Hirako Y; Sawamura D; Fujimoto W; Shimizu H
    J Invest Dermatol; 2017 Dec; 137(12):2552-2559. PubMed ID: 28842325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.